ReviewTherapeutic advances in gastroenterology2021
Economic burden and cost-effectiveness of therapies for
Review in Therapeutic advances in gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Alternative treatment of recurrentFrontiers in microbiology · 2024Pooled it
- Clostridioides difficile in West Africa: a systematic review of the limited evidence and key knowledge gaps.Global epidemiology · 2026Article
- AApplied and environmental microbiology · 2026Article
- Mechanisms by which proline reductase ofmBio · 2026Article
- Oral antibiotics prescribing patterns and associated diarrhea risk: Public health implications.Journal of public health research · 2026Article
- Role of TLR4 in Enteric Glia Response to Clostridioides Difficile Toxins: Insights From In Vivo and In Vitro Studies.Journal of cellular and molecular medicine · 2025Article
- The Ambivalent Nature ofToxins · 2025Review
- Unravelling three-way interactions betweenJournal of medical microbiology · 2025Review
- Immunotherapy for Infectious Diseases: Back to the Future.The Journal of infectious diseases · 2025Article
- Global, regional, and national age-sex-specific burden of diarrhoeal diseases, their risk factors, and aetiologies, 1990-2021, for 204 countries and territories: a systematic analysis for the Global Burden of Disease Study 2021.The Lancet. Infectious diseases · 2025Article
- Attributable Costs ofJournal of Korean medical science · 2025Article
- Non-antibiotic therapies for multidrug-resistant gastrointestinal infections: an overview of the use of probiotics, natural compounds, and bacteriophages.Frontiers in antibiotics · 2025Review
- Management of Clostridioides difficile infection: an Italian Delphi consensus.The Journal of antimicrobial chemotherapy · 2024Article
- Best Practices in the Management ofTropical medicine and infectious disease · 2024Review
- Article
- Clostridioides difficile infection, recurrence and the associated healthcare consumption in Sweden between 2006 and 2019: a population-based cohort study.BMC infectious diseases · 2024Article
- Treated, hospital-onsetInfection control and hospital epidemiology · 2024Article
- Vowst's FDA approval is a boon for the prevention of recurrentAnnals of medicine and surgery (2012) · 2023Article
- Article
- ClostridioidesGastroenterology & hepatology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.